CAJ | 학술논문

目的：探讨参芪汤对冠心病患者康复疗效的影响。方法：将冠心病患者80例随机分为治疗组和对照组各40例，对照组予常规治疗，治疗组在对照组治疗基础上予中医辨证施治。1个月为1个疗程，2个疗程后观察疗效。结果：治疗组总有效率为82.68%较对照组的69.33%高，差异有统计学意义(P＜0.05)，显效率21.22%高于对照组的7.38%，2组相比差异有统计学意义(P＜0.05)；2组中医证候积分较治疗前均下降(P＜0.05)，SF-36量表评分，治疗组患者在“身体疼痛”“活力”“情感职能”“精神健康”“健康变化”等维度积分方面明显高于对照组(P＜0.05)；6分钟步行试验2组比较差异具有统计学意义(P＜0.05)，2组左心室射血分数治疗前后比较差异具有统计学意义(P＜0.05)，但2组间比较差异无统计学意义(P＞0.05)。结论：参芪汤可改善冠心病患者临床症状；改善患者心功能,提高患者的生存质量，促进术后患者的康复过程。
목적：탐토삼기탕대관심병환자강복료효적영향。방법：장관심병환자80례수궤분위치료조화대조조각40례，대조조여상규치료，치료조재대조조치료기출상여중의변증시치。1개월위1개료정，2개료정후관찰료효。결과：치료조총유효솔위82.68%교대조조적69.33%고，차이유통계학의의(P＜0.05)，현효솔21.22%고우대조조적7.38%，2조상비차이유통계학의의(P＜0.05)；2조중의증후적분교치료전균하강(P＜0.05)，SF-36량표평분，치료조환자재“신체동통”“활력”“정감직능”“정신건강”“건강변화”등유도적분방면명현고우대조조(P＜0.05)；6분종보행시험2조비교차이구유통계학의의(P＜0.05)，2조좌심실사혈분수치료전후비교차이구유통계학의의(P＜0.05)，단2조간비교차이무통계학의의(P＞0.05)。결론：삼기탕가개선관심병환자림상증상；개선환자심공능,제고환자적생존질량，촉진술후환자적강복과정。
Objective: To explore the influence of ShenQiTang on the rehabilitation of the patients with coronary atherosclerotic heart disease. Methods:Eighty patients were randomized into the treatment group and the control group, 40 cases each group, the control group received routine treatment and the treatment group syndrome differentiation and treatment on the foundation of the treatment given to the control group. One month was one course of the treatment, curative effects were observed after two courses of the treatment. Results: Total effective rate of the treatment group was 82.68%, higher than 69.33%of the control group with significant difference (P<0.05), markedly effective rate of the treatment group was 21.22%, higher than 7.38%of the control group (P<0.05). TCM symptom scales of both groups were decreased compared with before treating (P<0.05), SF-36 scales showed that the treatment group was obviously higher than the control group in the dimension scales including body pain, vitality, role emotional, mental health, reported health transition and others (P<0.05). The comparison between both groups showed statistical difference in six minute walking test (P<0.05), the comparisons between before and after treating demonstrated statistical differences in left ventricular ejection fraction (LVEF) (P<0.05), but there was no statistical meaning between both groups (P>0.05). Conclusion:ShenQiTang could improve clinical symptom of the patients with coronary heart disease, improve heart function and life quality of the patients, and promote the recovery of the patients after the surgery.